The Evolution and Innovation of Pharmaceutical Technology: Implications for US Medicare
Modernization Act
A Pre-Meeting Symposium
Prior to the ISPOR 10th Annual International Meeting
Co-Sponsored by
ISPOR and PhRMA Health Outcomes Committee
SUNDAY, MAY 15, 2005,
5:00PM-7:00PM
MARRIOTT WARDMAN PARK HOTEL, WASHINGTON DC, USA
| The
symposium will highlight progress in hypertension, elevated
cholesterol, diabetes, congestive heart failure, asthma, and
depression over the past 40 years and link changes in therapeutic
guidelines. |
| 5:00-5:15 |
Introduction |
| |
Moderator: Joseph Jackson PhD, Group Director, Health Economic Policy and
External Relations, Bristol-Myers Squibb, Princeton, NJ, USA
|
|
5:15-6:00 |
Evolution and Innovation in Pharmaceutical Therapy |
| |
Speaker: Robert Dubois, MD, PhD, Senior Vice President, Cerner
Health Insights,
Beverly Hills, CA, USA |
| |
Why do more patients take more medications? A systematic
examination of
national guidelines and their evolution during the past three
decades reveals clear
themes. These data help to explain rising pharmaceutical
expenditures and provide
a framework for further research and policy.
|
| 6:00-6:45
|
Implications for
US Medicare Modernization Act |
|
Speaker:
Steven Phurrough MD, MPA, Director, Coverage and Analysis Group, Office of Clinical Standards & Quality Center for Medicare and Medicaid Services, Baltimore, MD, USA
What are Medicare's plans for collecting data post-coverage?
Medicare commonly finds that the evidence supporting medical
necessity for services and technologies is less than adequate for
CMS, providers and patients. This creates challenges for making
good medical decisions. CMS is interested in well designed studies
of observational data and supportive information to determine the
best prevention, diagnosis and treatment options.
|
| 6:45-7:00
|
Open Discussion |
| 7:00- 7:30 |
Reception |
 |
|
